Morphine in primary percutaneous coronary intervention-No pain, questionable gain.
Aadhavi SridharanCarey D KimmelstielPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
The clinical impact of concurrently administered morphine and P2Y12 inhibitors in primary percutaneous coronary intervention (PCI) is not well understood. Large, randomized clinical trials are required to assess clinical outcomes with concurrent morphine and P2Y12 inhibitor use in ST-segment elevation myocardial infarction patients undergoing PCI. Based on the currently available pharmacologic data, cautious use of morphine in primary PCI would seem prudent.
Keyphrases
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- acute myocardial infarction
- antiplatelet therapy
- acute coronary syndrome
- coronary artery bypass grafting
- patients undergoing
- atrial fibrillation
- coronary artery bypass
- chronic pain
- pain management
- radiation therapy
- squamous cell carcinoma
- neuropathic pain
- artificial intelligence
- left ventricular
- electronic health record
- rectal cancer